O	0	5	Short	Short	JJ	B-NP
O	6	13	pigment	pigment	NN	I-NP
O	14	24	epithelial	epithelial	NN	I-NP
O	24	25	-	-	HYPH	O
O	25	32	derived	derive	VBN	B-NP
O	33	39	factor	factor	NN	I-NP
O	39	40	-	-	HYPH	O
O	40	47	derived	derive	VBN	B-NP
O	48	55	peptide	peptide	NN	I-NP
O	56	64	inhibits	inhibit	VBZ	B-VP
O	65	77	angiogenesis	angiogenesis	NN	B-NP
O	78	81	and	and	CC	I-NP
B-Cancer	82	87	tumor	tumor	NN	I-NP
O	88	94	growth	growth	NN	I-NP
O	94	95	.	.	.	O

O	96	103	PURPOSE	PURPOSE	NN	B-NP
O	103	104	:	:	:	O
O	105	112	Pigment	Pigment	NN	B-NP
O	113	123	epithelial	epithelial	JJ	I-NP
O	123	124	-	-	HYPH	O
O	124	131	derived	derive	VBN	B-VP
O	132	138	factor	factor	NN	B-NP
O	139	140	(	(	(	O
O	140	144	PEDF	PEDF	NN	B-NP
O	144	145	)	)	)	O
O	146	148	is	be	VBZ	B-VP
O	149	150	a	a	DT	B-NP
O	151	157	potent	potent	JJ	I-NP
O	158	170	angiogenesis	angiogenesis	NN	I-NP
O	171	180	inhibitor	inhibitor	NN	I-NP
O	181	185	with	with	IN	B-PP
O	186	194	multiple	multiple	JJ	B-NP
O	195	200	other	other	JJ	I-NP
O	201	210	functions	function	NNS	I-NP
O	210	211	,	,	,	O
O	212	216	some	some	DT	B-NP
O	217	219	of	of	IN	B-PP
O	220	225	which	which	WDT	B-NP
O	226	233	enhance	enhance	VBP	B-VP
B-Cancer	234	239	tumor	tumor	NN	B-NP
O	240	246	growth	growth	NN	I-NP
O	246	247	.	.	.	O

O	248	251	Our	Our	PRP$	B-NP
O	252	260	previous	previous	JJ	I-NP
O	261	268	studies	study	NNS	I-NP
O	269	275	mapped	map	VBD	B-VP
O	276	280	PEDF	PEDF	NN	B-NP
O	281	295	antiangiogenic	antiangiogenic	JJ	I-NP
O	296	299	and	and	CC	I-NP
O	300	311	prosurvival	prosurvival	NN	I-NP
O	312	322	activities	activity	NNS	I-NP
O	323	325	to	to	TO	B-PP
O	326	334	distinct	distinct	JJ	B-NP
O	335	343	epitopes	epitope	NNS	I-NP
O	343	344	.	.	.	O

O	345	349	This	This	DT	B-NP
O	350	355	study	study	NN	I-NP
O	356	359	was	be	VBD	B-VP
O	360	365	aimed	aim	VBN	I-VP
O	366	368	to	to	TO	B-VP
O	369	378	determine	determine	VB	I-VP
O	379	382	the	the	DT	B-NP
O	383	390	minimal	minimal	JJ	I-NP
O	391	399	fragment	fragment	NN	I-NP
O	400	402	of	of	IN	B-PP
O	403	407	PEDF	PEDF	NN	B-NP
O	407	408	,	,	,	O
O	409	414	which	which	WDT	B-NP
O	415	424	maintains	maintain	VBZ	B-VP
O	425	439	antiangiogenic	antiangiogenic	JJ	B-NP
O	440	443	and	and	CC	I-NP
B-Cancer	444	453	antitumor	antitumor	JJ	I-NP
O	454	462	efficacy	efficacy	NN	I-NP
O	462	463	.	.	.	O

O	464	476	EXPERIMENTAL	EXPERIMENTAL	JJ	B-NP
O	477	483	DESIGN	DESIGN	NN	I-NP
O	483	484	:	:	:	O
O	485	487	We	We	PRP	B-NP
O	488	496	analyzed	analyze	VBD	B-VP
O	497	509	antigenicity	antigenicity	NN	B-NP
O	509	510	,	,	,	O
O	511	525	hydrophilicity	hydrophilicity	NN	B-NP
O	525	526	,	,	,	O
O	527	530	and	and	CC	O
O	531	537	charge	charge	NN	B-NP
O	538	550	distribution	distribution	NN	I-NP
O	551	553	of	of	IN	B-PP
O	554	557	the	the	DT	B-NP
O	558	573	angioinhibitory	angioinhibitory	JJ	I-NP
O	574	581	epitope	epitope	NN	I-NP
O	582	583	(	(	(	O
O	583	586	the	the	DT	B-NP
O	587	589	34	34	CD	I-NP
O	589	590	-	-	HYPH	I-NP
O	590	593	mer	mer	NN	I-NP
O	593	594	)	)	)	O
O	595	598	and	and	CC	O
O	599	607	designed	design	VBN	B-VP
O	608	613	three	three	CD	B-NP
O	614	622	peptides	peptide	NNS	I-NP
O	623	631	covering	cover	VBG	B-VP
O	632	635	its	its	PRP$	B-NP
O	636	640	COOH	COOH	NN	I-NP
O	641	649	terminus	terminus	NN	I-NP
O	649	650	,	,	,	O
O	651	654	P14	P14	NN	B-NP
O	654	655	,	,	,	O
O	656	659	P18	P18	NN	B-NP
O	659	660	,	,	,	O
O	661	664	and	and	CC	O
O	665	668	P23	P23	NN	B-NP
O	668	669	.	.	.	O

O	670	672	We	We	PRP	B-NP
O	673	681	analyzed	analyze	VBD	B-VP
O	682	687	their	their	PRP$	B-NP
O	688	695	ability	ability	NN	I-NP
O	696	698	to	to	TO	B-VP
O	699	704	block	block	VB	I-VP
B-Cell	705	716	endothelial	endothelial	JJ	B-NP
I-Cell	717	721	cell	cell	NN	I-NP
O	722	732	chemotaxis	chemotaxis	NN	I-NP
O	733	736	and	and	CC	O
O	737	743	induce	induce	VB	B-VP
O	744	753	apoptosis	apoptosis	NN	B-NP
O	754	756	in	in	FW	B-ADVP
O	757	762	vitro	vitro	FW	I-ADVP
O	763	766	and	and	CC	O
O	767	772	their	their	PRP$	B-NP
O	773	787	antiangiogenic	antiangiogenic	JJ	I-NP
O	788	796	activity	activity	NN	I-NP
O	797	799	in	in	FW	B-ADVP
O	800	804	vivo	vivo	FW	I-ADVP
O	804	805	.	.	.	O

O	806	809	The	The	DT	B-NP
O	810	818	selected	select	VBN	I-NP
O	819	826	peptide	peptide	NN	I-NP
O	827	830	was	be	VBD	B-VP
O	831	837	tested	test	VBN	I-VP
O	838	841	for	for	IN	B-PP
O	842	845	the	the	DT	B-NP
B-Cancer	846	855	antitumor	antitumor	JJ	I-NP
O	856	864	activity	activity	NN	I-NP
O	865	872	against	against	IN	B-PP
O	873	879	mildly	mildly	RB	B-NP
O	880	890	aggressive	aggressive	JJ	I-NP
O	891	902	xenografted	xenografte	VBN	I-NP
B-Cancer	903	911	prostate	prostate	NN	I-NP
I-Cancer	912	921	carcinoma	carcinoma	NN	I-NP
O	922	925	and	and	CC	O
O	926	932	highly	highly	RB	B-NP
O	933	943	aggressive	aggressive	JJ	I-NP
B-Cancer	944	949	renal	renal	JJ	I-NP
I-Cancer	950	954	cell	cell	NN	I-NP
I-Cancer	955	964	carcinoma	carcinoma	NN	I-NP
O	964	965	.	.	.	O

O	966	968	To	To	TO	B-VP
O	969	975	verify	verify	VB	I-VP
O	976	980	that	that	IN	B-SBAR
O	981	984	P18	P18	NN	B-NP
O	985	989	acts	act	VBZ	B-VP
O	990	992	in	in	IN	B-PP
O	993	996	the	the	DT	B-NP
O	997	1001	same	same	JJ	I-NP
O	1002	1008	manner	manner	NN	I-NP
O	1009	1011	as	as	IN	B-PP
O	1012	1016	PEDF	PEDF	NN	B-NP
O	1016	1017	,	,	,	O
O	1018	1020	we	we	PRP	B-NP
O	1021	1025	used	use	VBD	B-VP
O	1026	1046	immunohistochemistry	immunohistochemistry	NN	B-NP
O	1047	1049	to	to	TO	B-VP
O	1050	1057	measure	measure	VB	I-VP
O	1058	1062	PEDF	PEDF	NN	B-NP
O	1063	1070	targets	target	NNS	I-NP
O	1070	1071	,	,	,	O
O	1072	1080	vascular	vascular	JJ	B-NP
O	1081	1092	endothelial	endothelial	JJ	I-NP
O	1093	1099	growth	growth	NN	I-NP
O	1100	1106	factor	factor	NN	I-NP
O	1107	1115	receptor	receptor	NN	I-NP
O	1116	1117	2	2	CD	B-NP
O	1117	1118	,	,	,	O
O	1119	1122	and	and	CC	O
O	1123	1127	CD95	CD95	NN	B-NP
O	1128	1134	ligand	ligand	NN	I-NP
O	1135	1145	expression	expression	NN	I-NP
O	1146	1148	in	in	IN	B-PP
O	1149	1152	P18	P18	NN	B-NP
O	1152	1153	-	-	HYPH	B-NP
O	1153	1160	treated	treat	VBN	I-NP
B-Multi-tissue_structure	1161	1172	vasculature	vasculature	NN	I-NP
O	1172	1173	.	.	.	O

O	1174	1181	RESULTS	RESULTS	NNS	B-NP
O	1181	1182	:	:	:	O
O	1183	1186	P14	P14	NN	B-NP
O	1187	1190	and	and	CC	I-NP
O	1191	1194	P18	P18	NN	I-NP
O	1195	1202	blocked	block	VBD	B-VP
B-Cell	1203	1214	endothelial	endothelial	JJ	B-NP
I-Cell	1215	1219	cell	cell	NN	I-NP
O	1220	1230	chemotaxis	chemotaxis	NN	I-NP
O	1230	1231	;	;	:	O
O	1232	1235	P18	P18	NN	B-NP
O	1236	1239	and	and	CC	I-NP
O	1240	1243	P23	P23	NN	I-NP
O	1244	1251	induced	induce	VBD	B-VP
O	1252	1261	apoptosis	apoptosis	NN	B-NP
O	1261	1262	.	.	.	O

O	1263	1266	P18	P18	NN	B-NP
O	1267	1273	showed	show	VBD	B-VP
O	1274	1277	the	the	DT	B-NP
O	1278	1285	highest	high	JJS	I-NP
O	1286	1290	IC50	IC50	NN	I-NP
O	1291	1294	and	and	CC	O
O	1295	1302	blocked	block	VBD	B-VP
O	1303	1315	angiogenesis	angiogenesis	NN	B-NP
O	1316	1318	in	in	FW	B-ADVP
O	1319	1323	vivo	vivo	FW	I-ADVP
O	1323	1324	:	:	:	O
O	1325	1328	P23	P23	NN	B-NP
O	1329	1332	was	be	VBD	B-VP
O	1333	1341	inactive	inactive	JJ	B-ADJP
O	1342	1345	and	and	CC	O
O	1346	1349	P14	P14	NN	B-NP
O	1350	1353	was	be	VBD	B-VP
O	1354	1367	proangiogenic	proangiogenic	JJ	B-ADJP
O	1367	1368	.	.	.	O

O	1369	1372	P18	P18	NN	B-NP
O	1373	1382	increased	increase	VBD	B-VP
O	1383	1386	the	the	DT	B-NP
O	1387	1397	production	production	NN	I-NP
O	1398	1400	of	of	IN	B-PP
O	1401	1405	CD95	CD95	NN	B-NP
O	1406	1412	ligand	ligand	NN	I-NP
O	1413	1416	and	and	CC	O
O	1417	1424	reduced	reduce	VBD	B-VP
O	1425	1428	the	the	DT	B-NP
O	1429	1439	expression	expression	NN	I-NP
O	1440	1442	of	of	IN	B-PP
O	1443	1451	vascular	vascular	JJ	B-NP
O	1452	1463	endothelial	endothelial	JJ	I-NP
O	1464	1470	growth	growth	NN	I-NP
O	1471	1477	factor	factor	NN	I-NP
O	1478	1486	receptor	receptor	NN	I-NP
O	1487	1488	2	2	CD	B-NP
O	1489	1491	by	by	IN	B-PP
O	1492	1495	the	the	DT	B-NP
B-Cell	1496	1507	endothelial	endothelial	JJ	I-NP
I-Cell	1508	1513	cells	cell	NNS	I-NP
O	1514	1516	in	in	FW	B-ADVP
O	1517	1521	vivo	vivo	FW	I-ADVP
O	1521	1522	.	.	.	O

O	1523	1525	In	In	IN	B-PP
B-Cancer	1526	1531	tumor	tumor	NN	B-NP
O	1532	1539	studies	study	NNS	I-NP
O	1539	1540	,	,	,	O
O	1541	1544	P18	P18	NN	B-NP
O	1545	1548	was	be	VBD	B-VP
O	1549	1553	more	more	RBR	B-ADJP
O	1554	1563	effective	effective	JJ	I-ADJP
O	1564	1566	in	in	IN	B-PP
O	1567	1575	blocking	block	VBG	B-VP
O	1576	1579	the	the	DT	B-NP
O	1580	1592	angiogenesis	angiogenesis	NN	I-NP
O	1593	1596	and	and	CC	I-NP
O	1597	1603	growth	growth	NN	I-NP
O	1604	1606	of	of	IN	B-PP
O	1607	1610	the	the	DT	B-NP
B-Cancer	1611	1619	prostate	prostate	NN	I-NP
I-Cancer	1620	1626	cancer	cancer	NN	I-NP
O	1627	1631	than	than	IN	B-PP
O	1632	1640	parental	parental	JJ	B-NP
O	1641	1643	34	34	CD	I-NP
O	1643	1644	-	-	HYPH	I-NP
O	1644	1647	mer	mer	NN	I-NP
O	1647	1648	;	;	:	O
O	1649	1651	in	in	IN	B-PP
O	1652	1655	the	the	DT	B-NP
B-Cancer	1656	1661	renal	renal	JJ	I-NP
I-Cancer	1662	1666	cell	cell	NN	I-NP
I-Cancer	1667	1676	carcinoma	carcinoma	NN	I-NP
O	1676	1677	,	,	,	O
O	1678	1681	P18	P18	NN	B-NP
O	1682	1690	strongly	strongly	RB	B-ADVP
O	1691	1700	decreased	decrease	VBD	B-VP
O	1701	1713	angiogenesis	angiogenesis	NN	B-NP
O	1714	1717	and	and	CC	O
O	1718	1724	halted	halt	VBD	B-VP
O	1725	1728	the	the	DT	B-NP
O	1729	1740	progression	progression	NN	I-NP
O	1741	1743	of	of	IN	B-PP
O	1744	1755	established	establish	VBN	B-NP
B-Cancer	1756	1762	tumors	tumor	NNS	I-NP
O	1762	1763	.	.	.	O

O	1764	1775	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1775	1776	:	:	:	O
O	1777	1780	P18	P18	NN	B-NP
O	1781	1783	is	be	VBZ	B-VP
O	1784	1785	a	a	DT	B-NP
O	1786	1791	novel	novel	JJ	I-NP
O	1792	1795	and	and	CC	I-NP
O	1796	1802	potent	potent	JJ	I-NP
O	1803	1817	antiangiogenic	antiangiogenic	JJ	I-NP
O	1818	1832	biotherapeutic	biotherapeutic	JJ	I-NP
O	1833	1838	agent	agent	NN	I-NP
O	1839	1843	that	that	WDT	B-NP
O	1844	1847	has	have	VBZ	B-VP
O	1848	1857	potential	potential	JJ	B-ADJP
O	1858	1860	to	to	TO	B-VP
O	1861	1863	be	be	VB	I-VP
O	1864	1873	developed	develop	VBN	I-VP
O	1874	1877	for	for	IN	B-PP
O	1878	1881	the	the	DT	B-NP
O	1882	1891	treatment	treatment	NN	I-NP
O	1892	1894	of	of	IN	B-PP
B-Cancer	1895	1903	prostate	prostate	NN	B-NP
O	1904	1907	and	and	CC	O
B-Cancer	1908	1913	renal	renal	JJ	B-NP
I-Cancer	1914	1920	cancer	cancer	NN	I-NP
O	1920	1921	.	.	.	O

